SharePoint
A- A A+

For Patients & Visitors

Find a Doctor

Find a Doctor

Associate Professor Tan Poh Lin

Photo of Associate Professor Tan Poh Lin
Credential:
MBBS (S'pore), MMED (Paediatrics), FAMS (S'pore), FRCPCH (UK)
Designation:
Senior Consultant, Division of Paediatric Haematology and Oncology, Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Hospital

Clinical Director, Paediatric Oncology and Blood / Marrow Transplantation (BMT) Programme [FACT accredited programme], NUH

Associate Programme Director (Paediatric Residency), NUHS

Programme Director, Advanced Clinical Fellowship in Paediatric BMT, NUHS 

Clinical Associate Professor, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore

Programme Director, Diploma in Paediatric Cancer Care, Academy of Medicine, Singapore 
Specialty:
Paediatrics
Sub Specialty:
Paediatric Blood and Marrow Transplantation (BMT) Programme, Paediatric Haematology-Oncology
Medical and Surgical Conditions:
Cell-based Therapy, Childhood Cancer, Childhood Leukaemia, Haemophilia (Children), Immunodeficiency Disease, Langerhan Cell Histiocytosis, Lymphoma (Children), Neuroblastoma, Neutropenic Fever (Children)
Special Interest:
  • Paediatric Blood / Marrow
  • Transplant & Cell Therapy
  • Paediatric Haematology-Oncology
  • Paediatric Immunodeficiency Diseases & HLH
  • Blood / Marrow Transplant (BMT), Advanced Cellular Therapy (ACT) & Survivorship 
  • Primary immunodeficiency and EBV related disorders
  • Physician health and medical education
Institution:
National University Hospital
National University Cancer Institute, Singapore
National University Health System
Associate Professor Tan Poh Lin graduated with MBBS (S’pore) in 1992 and Master of Medicine in Paediatrics (S’pore) in 1996. She is a registered specialist in Paediatric Medicine and Paediatric Haematology & Oncology. Her main practice is in the field of blood/marrow transplantation (BMT) for cancer and non-cancer indications. Some examples of HCT that A/Prof Tan is experienced in are bone marrow transplant, peripheral blood stem cell transplant and umbilical cord blood transplant. She is experienced in tailoring therapy that best serve the patient’s unique medical needs within the context of mainstream therapy.

HCT is a potential cure for childhood cancers including certain high risk leukaemia (e.g. acute lymphoblastic leukaemia, acute myeloid leukaemia, juvenile myelomonocytic leukaemia, myelodysplastic syndrome, chronic myeloid leukaemia, therapy-related acute leukaemia) and solid tumours (e.g. Medulloblastoma, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma). HCT is also a curative treatment option for specific blood disorders including congenital anaemia, transfusion-dependent Thalassaemia, bone marrow failure syndromes (e.g. Fanconi Anemia, Dyskeratosis Congenita, Diamond Blackfan Anaemia or Pure Red Cell Aplasia, severe idiopathic aplastic anaemia), primary immunodeficiency diseases (e.g. Severe Combined Immune Deficiency, Chronic Granulomatous Disease, Wiskott-Aldrich Syndrome, Natural Killer Cell Deficiency or Haemophagocytic Lymphohistiocytosis) and rare genetic diseases such as Cerebral Adrenoleukodystrophy (ALD) and Hurler’s Syndrome if diagnosed early.

A/Prof Tan is experienced in the use of adoptive transfer of immune cells such as Natural Killer and T cells that can be given before or after HCT to rescue patients with cancer progression or relapse. She champions a multidisciplinary survivorship programme that focuses on primary and secondary diseases surveillance as well as quality of life of patients. She has a special interest in developing expertise in Adolescent and Young Adult oncology (AYA) to fill current gaps in the care of this special group of patients.

A/Prof Tan believes that the cure of catastrophic or any disease needs to be managed in the context of holistic care with emphasis on good symptom(s) control throughout the illness and thoughtful recovery support for re-integration back to society. She works with an excellent team of paediatricians with various specialties, nurses, social workers and allied health personnel towards delivering the best of such care.

A/Prof Tan believes that teaching (patients, parents and next generation of doctors), good clinical and translational research as well as clinical medicine are inseparable entities and excellent health care must be delivered in a collaborative and coordinated effort. She serves in various teaching capacities within and out of the NUHS campus. A/Prof Tan also serves as the Chair of the Viva-Asia Blood & Marrow Transplant Consortium, a voluntary organisation of paediatric stem cell transplant experts from ASEAN and the region, working towards improving the practice of HCT. She hopes to improve the health of every child and family who entrust themselves to our team.


Research
Ongoing
  1. EBV related lymphoproliferative disorders in Asians

  2. Adoptive cellular therapy using haploidentical natural killer cells in treatment of refractory AML, ALL, soft tissue sarcoma and neuroblastoma (NCT01974479, NCT02123836, NCT02409576, NCT03242603, NCT02315118)

Professional Memberships

  • Singapore Paediatric Society
  • Paediatric Oncology Group (Singapore) 
  • VIVA-Asia Blood/ Marrow Transplant Consortium (VABMT)
  • American Society of Hematology (USA) 
  • American Society for Blood and Marrow Transplantation (USA)

Research and Publications

  1. Ng SB, Ohshima K, Selvarajan V, Huang G, Choo SN, Tan PL, … Chng WJ (2015). Epstein – Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype. Leukemia & Lymphoma, 56(8):2408-15. doi: 10.3109/10428194.2014.983099

  2. Tan PL, Lim LM, Khanlian C, Villegas MS (2014). A Single Center Experience of Cytomegalovirus Infections in Asian Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Leukemia in Singapore. Transplant infectious disease an official journal of the Transplantation Society, 16(4):556-60. doi: 10.1111/tid.12238

  3. Chen J, Lee V, Luo CJ, Chiang AK, Hongeng S, Tan PL, . . . Okamoto Y (2013). Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group. British Journal of Haematology, 162(3):383-91. doi: 10.1111/bjh.12405

  4. Lee AJ, Wu J, Villegas MS, Shek LP, Lee BW, Tan PL (2012). Stem Cell Transplantation for Primary Immunodeficiency Disease: Experience of a Singapore Hospital. The World Allergy Organization Journal, 5(3):41-4. doi: 10.1097/WOX.0b013e31824af5e3

  5. Tan PL, Wagner JE, Auerbach AD, Defor TE, Slungaard A, Macmillan ML (2006). Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatric Blood & Cancer, 46(5):630-6.

  6. Tan PH, Hwang WY, Goh YT, Tan PL, Koh LP, Tan CH, Quah TC (2004). Unrelated Peripheral Blood and Cord Blood Hematopoietic Stem Cell transplants for Thalassaemia Major. American Journal of Hematology, 75(4):209-12.

  7. For more publications, please refer to https://scholar.google.com.sg/citations?user=m3sMwjoAAAAJ&hl=en